InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,505.00
(
-0.71%
)
US TECH 100
19,000.00
(
-0.94%
)
Dow Jones
40,287.53
(
-0.93%
)
Brent Oil
81.88
(
0.00%
)
Bitcoin
67,111.52
(
-0.09%
)
Post# of 4974718
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

CABRALEES

Send PM Follow Ignore
Followers 5
Posts 2376
Boards Moderated 0
Alias Born 04/03/2001

CABRALEES

Member Level

Re: None

Friday, 03/02/2007 2:51:50 PM

Friday, March 02, 2007 2:51:50 PM

Post# of 4974718
INSM hanging in there. FYI found this note by Lazard

Insmed "buy"

Monday, February 19, 2007 4:07:30 AM ET
Lazard Capital Markets

NEW YORK, February 19 (newratings.com) - Analysts at Lazard Capital maintain their "buy" rating on Insmed Inc (ticker: INSM). The target price is set to $3.

In a research note published on February 16, the analysts mention that as a result of stipulation submitted to the court by Insmed and Tercica, the preliminary injunction hearing has been delayed. The reasons for the delay in the hearing and when it would be scheduled appear uncertain, the analysts say.


Recommend this article to a friend



INSM.NAS | detailed quote - chart - all headlines - add to watchlist

CABBY

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up